GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

 

 

TABLE OF CONTENTS

1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.3. KEY INSIGHTS

2.3.1. USAGE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE

2.3.2. R&D INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA

2.3.3. DEMAND FOR PERSONALIZED MEDICINES 

2.4. IMPACT OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.5. PORTER’S FIVE FORCES ANALYSIS

2.6. MARKET ATTRACTIVENESS MATRIX

2.7. VENDOR SCORECARD

2.8. INDUSTRY COMPONENTS

2.8.1. RESEARCH & DEVELOPMENT (R & D)

2.8.2. RAW MATERIALS

2.8.3. MANUFACTURING

2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS

2.8.5. END-USER

2.9. KEY IMPACT ANALYSIS

2.9.1. EFFECTIVENESS

2.9.2. PRICE

2.9.3. SAFETY

2.10. KEY MARKET STRATEGIES

2.10.1. ACQUISITIONS

2.10.2. PRODUCT LAUNCHES

2.10.3. CONTRACTS & AGREEMENTS

2.10.4. INVESTMENTS & EXPANSIONS

2.11. MARKET DRIVERS

2.11.1. PREVALENCE OF ALZHEIMER’S DISEASE

2.11.2. RISE IN THE ELDERLY POPULATION

2.12. MARKET CHALLENGES

2.12.1. FAILURE OF LATE-STAGE DRUGS

2.12.2. STRINGENT GOVERNMENT REGULATIONS

2.13. MARKET OPPORTUNITIES

2.13.1. EMERGENCE OF NEW DIAGNOSTIC TECHNOLOGIES

2.13.2. GROWING NUMBER OF PIPELINE DRUGS

3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS

3.1. BY DRUG TYPE

3.1.1. MARKETED DRUGS

3.1.2. PIPELINE DRUGS

3.2. BY DISEASE STAGE

3.2.1. LATE STAGE: SEVERE AD

3.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.2.3. PRODROMAL STAGE

3.3. BY GENERIC & BRANDED

3.3.1. BRANDED

3.3.2. GENERIC

4. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS

4.1. LUMBAR PUNCTURE TEST

4.2. POSITRON EMISSION TOMOGRAPHY

4.3. ELECTROENCEPHALOGRAPHY

4.4. MAGNETIC RESONANCE IMAGING

4.5. COMPUTED TOMOGRAPHY

4.6. BLOOD TEST

4.7. OTHER DIAGNOSTICS

5. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK

5.1. NORTH AMERICA

5.1.1. MARKET BY THERAPEUTICS

5.1.1.1. MARKET BY DRUG TYPE

5.1.1.2. MARKET BY DISEASE STAGE

5.1.1.3. MARKET BY GENERIC & BRANDED

5.1.2. MARKET BY DIAGNOSTICS

5.1.3. COUNTRY ANALYSIS

5.1.3.1. UNITED STATES

5.1.3.2. CANADA

5.2. EUROPE

5.2.1. MARKET BY THERAPEUTICS

5.2.1.1. MARKET BY DRUG TYPE

5.2.1.2. MARKET BY DISEASE STAGE

5.2.1.3. MARKET BY GENERIC & BRANDED

5.2.2. MARKET BY DIAGNOSTICS

5.2.3. COUNTRY ANALYSIS

5.2.3.1. UNITED KINGDOM

5.2.3.2. GERMANY

5.2.3.3. FRANCE

5.2.3.4. ITALY

5.2.3.5. SPAIN

5.2.3.6. REST OF EUROPE

5.3. ASIA-PACIFIC

5.3.1. MARKET BY THERAPEUTICS

5.3.1.1. MARKET BY DRUG TYPE

5.3.1.2. MARKET BY DISEASE STAGE

5.3.1.3. MARKET BY GENERIC & BRANDED

5.3.2. MARKET BY DIAGNOSTICS

5.3.3. COUNTRY ANALYSIS

5.3.3.1. CHINA

5.3.3.2. JAPAN

5.3.3.3. INDIA

5.3.3.4. SOUTH KOREA

5.3.3.5. ASEAN COUNTRIES

5.3.3.6. AUSTRALIA AND NEW ZEALAND

5.3.3.7. REST OF ASIA-PACIFIC

5.4. LATIN AMERICA

5.4.1. MARKET BY THERAPEUTICS

5.4.1.1. MARKET BY DRUG TYPE

5.4.1.2. MARKET BY DISEASE STAGE

5.4.1.3. MARKET BY GENERIC & BRANDED

5.4.2. MARKET BY DIAGNOSTICS

5.4.3. COUNTRY ANALYSIS

5.4.3.1. BRAZIL

5.4.3.2. MEXICO

5.4.3.3. REST OF LATIN AMERICA

5.5. MIDDLE EAST AND AFRICA

5.5.1. MARKET BY THERAPEUTICS

5.5.1.1. MARKET BY DRUG TYPE

5.5.1.2. MARKET BY DISEASE STAGE

5.5.1.3. MARKET BY GENERIC & BRANDED

5.5.2. MARKET BY DIAGNOSTICS

5.5.3. COUNTRY ANALYSIS

5.5.3.1. UNITED ARAB EMIRATES

5.5.3.2. TURKEY

5.5.3.3. SAUDI ARABIA

5.5.3.4. SOUTH AFRICA

5.5.3.5. REST OF MIDDLE EAST & AFRICA

6. COMPETITIVE LANDSCAPE

6.1. BAXTER INTERNATIONAL INC

6.2. F. HOFFMANN-LA ROCHE AG

6.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)

6.4. NOVARTIS AG

6.5. PFIZER INC

6.6. SIEMENS HEALTHINEERS AG

6.7. AMARANTUS BIOSCIENCE HOLDINGS INC

6.8. EISAI CO LTD

6.9. ELI LILLY & COMPANY

6.10. LUPIN LIMITED

6.11. MERCK AND CO

6.12. BIOGEN INC

6.13. COGNOPTIX INC

6.14. GE HEALTHCARE

6.15. JOHNSON AND JOHNSON

6.16. SUN PHARMACEUTICALS INDUSTRIES LTD

6.17. TEVA PHARMACEUTICAL INDUSTRIES LTD

6.18. ZYDUS CADILA

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

 

TABLE LIST

TABLE 1: MARKET ATTRACTIVENESS MATRIX      

TABLE 2: VENDOR SCORECARD       

TABLE 3: KEY STRATEGIC DEVELOPMENTS

TABLE 4: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 5: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)        

TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION) 

TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)  

TABLE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)         

TABLE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)    

TABLE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)       

TABLE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)

TABLE 14: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION) 

TABLE 15: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)         

TABLE 16: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 17: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 18: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)        

TABLE 19: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION) 

TABLE 20: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)  

TABLE 21: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 22: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 23: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 24: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)       

TABLE 25: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)

TABLE 26: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION) 

TABLE 27: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 28: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 29: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 30: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)       

TABLE 31: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)

TABLE 32: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION) 

TABLE 33: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 34: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 35: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)        

TABLE 36: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)

TABLE 37: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)         

TABLE 38: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)    

TABLE 39: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)        

         

FIGURE LIST

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: KEY IMPACT ANALYSIS

FIGURE 3: TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS

FIGURE 4: INDUSTRY COMPONENTS          

FIGURE 5: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021 & 2028 (IN %)

FIGURE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)

FIGURE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN %)

FIGURE 10: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)

FIGURE 11: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)

FIGURE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)

FIGURE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 & 2028 (IN %)

FIGURE 14: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)

FIGURE 15: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)

FIGURE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021 & 2028 (IN %)

FIGURE 17: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)

FIGURE 18: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 19: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 20: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)

FIGURE 21: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 22: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)

FIGURE 23: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)

FIGURE 24: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)    

FIGURE 25: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 26: CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 27: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 28: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 29: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 30: ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 31: SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 32: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 33: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 34: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 35: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 36: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 37: ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 38: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

FIGURE 39: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

FIGURE 40: BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 41: MEXICO ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 42: REST OF LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 43: UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

FIGURE 44: SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 45: TURKEY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 46: SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 47: REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

 

 

North America is the leading region in the global market for Alzheimer’s disease therapeutics and diagnostics.

 

MARKET OUTLOOK

Triton estimates the global Alzheimer’s disease therapeutics and diagnostics market to grow with a CAGR of 6.98% in the years 2022-2028.

The high prevalence of Alzheimer’s disease (AD) and the growing elderly populace are key factors driving the growth of this market. The elderly population is at an increased risk of developing this disease, which is expected to aid the demand for therapeutics and diagnostics. However, stringent regulations by the government, as well as the failure of the late-stage drugs in clinical trials, are hampering the growth of this industry. On the bright side, the emergence of novel diagnostic technologies for AD treatment is creating new avenues for the market’s development.

 

Get more insights the Global Alzheimer’s Disease Therapeutics And Diagnostic Market:

 

https://www.tritonmarketresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostic-market

 

REGIONAL OUTLOOK

The global market for Alzheimer’s therapeutics and diagnostics spans Europe, the Asia-Pacific, Latin America, the Middle East and Africa, and North America. 

North America held the largest share in the global market in 2021, and is anticipated to maintain its lead by the end of the forecast period. Developed nations, such as the US and Canada, are considered in the market in this region. Factors such as the rising geriatric population and the growing burden of Alzheimer’s disease contribute to the growth of the market in North America. Statistics indicate that 1 in every 9 people in the US, aged 65 years or older, is affected by AD. This has enhanced the demand for developing novel therapeutics and diagnostics for Alzheimer’s.

COMPETITIVE OUTLOOK

Some of the major players engaged in the Alzheimer’s disease therapeutics and diagnostics market include Teva Pharmaceutical Industries Ltd, Pfizer Inc, Sun Pharmaceuticals Industries Ltd, Lupin Limited, GE Healthcare, Novartis AG, Eisai Co Ltd, Allergan Plc (acquired by Abbvie), Siemens Healthineers AG, Biogen Inc, Johnson and Johnson, Baxter International Inc, Zydus Cadila, Amarantus Bioscience Holdings Inc, Cognoptix Inc, Merck and Co, Eli Lilly & Company, and F. Hoffmann-La Roche AG.

Allergan Plc (acquired by Abbvie) is a leading name in the pharmaceutical industry that develops, manufactures, markets, and distributes biosimilar, specialty branded, and over-the-counter medications. The company has strengthened its product portfolio as a result of various new product launches and approvals. NAMZARIC, one of its products, aids in the treatment of moderate to severe Alzheimer’s disease symptoms. The company, which was founded in 2013, employs more than 1,200 people worldwide. It has a business presence in a number of nations, including the US, China, Canada, India, and other fast-growing markets in Europe, the Middle East, Latin America, and Southeast Asia. The company was acquired by AbbVie in May 2020.

 

 

SEGMENTATION

1. BAXTER INTERNATIONAL INC

2. F. HOFFMANN-LA ROCHE AG

3. ALLERGAN PLC (ACQUIRED BY ABBVIE)

4. NOVARTIS AG

5. PFIZER INC

6. SIEMENS HEALTHINEERS AG

7. AMARANTUS BIOSCIENCE HOLDINGS INC

8. EISAI CO LTD

9. ELI LILLY & COMPANY

10. LUPIN LIMITED

11. MERCK AND CO

12. BIOGEN INC

13. COGNOPTIX INC

14. GE HEALTHCARE

15. JOHNSON AND JOHNSON

16. SUN PHARMACEUTICALS INDUSTRIES LTD

17. TEVA PHARMACEUTICAL INDUSTRIES LTD

18. ZYDUS CADILA